Emerging Cancer Vaccines:Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition.pdf
《Emerging Cancer Vaccines:Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition.pdf》由会员分享,可在线阅读,更多相关《Emerging Cancer Vaccines:Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition.pdf(286页珍藏版)》请在三一文库上搜索。
1、Cancer Vaccines Rures adquireret umbraculi, etiam tremulus matrimonii libere senesceret app October 2008 Kalorama Information A division of MarketR 38 East 29th Street Sixth Floor New York, New York 10016 212.807 .2660 t 800.298.5603 t 212.807 .2676 f Copyright 2008 Kalorama Information Reproductio
2、n without written permission, in any media now in existence or hereafter developed, in whole or in any part, is strictly prohibited CANCER VACCINES: MARKETS, NEW DEVELOPMENTS, AND PIPELINE ANALYSIS A KALORAMA INFORMATION MARKET INTELLIGENCE REPORT Cancer Vaccine Markets has been prepared by Kalorama
3、 Information. We serve business and industrial clients in the United States and abroad with a complete line of information services and research publications. Kalorama Information Market Intelligence Reports are specifically designed to aid the action-oriented executive by providing a thorough prese
4、ntation of essential data and concise analysis. Author: Melissa Elder Publication Date: November 2008 38 East 29th Street New York, New York 10016 (800) 298-5699 Outside the U.S. (212) 807-2657 FAX: (212) 807-2676 www.KaloramaI E-MAIL: KLI1646591 Copyright 2008 Kalorama Information Reproduction wit
5、hout written permission, in any media now in existence or hereafter developed, in whole or in any part, is strictly prohibited BLANK iii Copyright 2008 Kalorama Information Reproduction without written permission, in any media now in existence or hereafter developed, in whole or in any part, is stri
6、ctly prohibited TABLE OF CONTENTS CHAPTER ONE: EXECUTIVE SUMMARY1 Introduction.1 Scope and Methodology3 Size and Growth of the Market5 Issues and Trends Affecting Market8 Leading Competitors.9 CHAPTER TWO: INTRODUCTION.11 Introduction.11 History and Growth of the Cancer Treatment Market .12 Types of
7、 Vaccines 14 Antigen/Adjuvant Vaccines.16 Whole Cell Tumor Vaccines17 Dendritic Cell (DC) Vaccines.17 Viral Vectors and DNA Vaccines17 Idiotype Vaccines18 Types of Therapeutic Vaccines.18 Patient-Specific Vaccines .18 Prostate Specific Antigen19 Sialyl Tn19 Heat Shock Proteins19 Ganglioside Molecule
8、s .20 Carcinoembryonic Antigen (CEA)20 MART-1.20 Tyrosinase.20 Adjuvants 20 Industry Structure.22 Demographics and Statistics.23 Growing and Aging Population.28 Life Expectancy and Cancer .34 CHAPTER THREE: CERVICAL CANCER VACCINES.37 Overview.37 Description of Vaccines on the Market41 Gardasil/Silg
9、ard .41 Cervarix42 Table of Contents iv Copyright 2006 Kalorama Information Reproduction without prior written permission, in any media now in existence or hereafter developed, In whole or in any part, is strictly prohibited. Description of Vaccines in Development.42 TG 4001/R348442 HspE7.42 Lovaxin
10、 C .43 VGX-3100.43 CA-9 .44 Market Summary46 Current and Potential Competitors and Analysis, 201249 CHAPTER FOUR: COLON/RECTAL CANCER VACCINES.53 Overview53 Description of Vaccines on the Market.57 OncoVAX57 Description of Vaccines in Development.57 OncoVAX57 TroVAX.58 Avicine58 CEA VRP Vaccine59 Co
11、llidem.59 IMA910.59 Lapuleucel-T.59 Oncophage .60 CDX-1307-01.60 Tumor Associated Antigen Therapeutic Vaccine CEA DNA Cancer Vaccine 61 MKC1106-PP.61 Market Summary64 Potential Competitors and Analysis, 201267 CHAPTER FIVE: LUNG CANCER VACCINES69 Overview69 Description of Vaccines in Development.74
12、Lucanix.74 MAGE-A3 Peptide74 Stimuvax.74 EGF Cancer Vaccine75 GV-1001.75 HyperAcute Lung75 IDM 2101 (EP-2101)76 Oncophage .76 INGN 225 .77 TG 401077 LungVAX 77 Tumor Associated Antigen Therapeutic Vaccine CEA DNA Cancer Vaccine 78 v New Developments in the Cancer Vaccine Market Copyright 2006 Kalora
13、ma Information Reproduction without prior written permission, in any media now in existence or hereafter developed, In whole or in any part, is strictly prohibited. DC Vax78 L523S78 Market Summary81 Potential Competitors and Analysis, 2012.82 CHAPTER SIX: LYMPHOMA VACCINES .83 Overview.83 Descriptio
14、n of Vaccines in Development.88 MyVax.88 BiovaxID.88 FavId.89 TG 104289 Market Summary91 Potential Competitors and Analysis, 2012.94 CHAPTER SEVEN: MELANOMA VACCINES.99 Overview.99 Description of Vaccines on the Market103 Description of Vaccines in Development.104 M-VAX 104 GMK .104 Allovectin-7.105
15、 MDX-1379 with Combination Treatment MDX-010 105 Oncophage106 MAGE-A3 ASCI107 Uvidem107 AGI-101H Vaccine108 ALVAC Vaccine 108 HyperAcute Melanoma.108 Market Summary111 Potential Competitors and Analysis, 2012.115 CHAPTER EIGHT: PROSTATE CANCER VACCINES119 Overview.119 Description of Vaccines in Deve
16、lopment.123 Provenge.123 DCVax-Prostate123 GVAX124 ProstAtak 124 TroVAX.125 Table of Contents vi Copyright 2006 Kalorama Information Reproduction without prior written permission, in any media now in existence or hereafter developed, In whole or in any part, is strictly prohibited. Telomerase Cancer
17、 Vaccine.125 MVA-BN Prostate.125 HyperAcute Prostate 126 MKC1106-PP.126 Market Summary129 Potential Competitors and Analysis, 2012133 CHAPTER NINE: BREAST CANCER VACCINES.137 Overview137 Description of Vaccines in Development.143 INGN 225 .143 CEA VRP Vaccine143 MVA-BN HER2.143 Lapuleucel-T.143 PX 1
18、04.1.144 CDX-1307-02.144 Tumor Associated Antigen Therapeutic Vaccine CEA DNA Cancer Vaccine 144 MKC1106-PP.145 Market Summary147 CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES.149 Overview149 Description of Vaccines in Development.155 GV 1001155 GI-4000 155 Avicine155 GVAX156 HyperAcute Pancreas.156
19、 Oncophage .156 CDX-1307-01.157 CRS-100 .157 CRS-207 .157 DC Vax.157 MKC1106-PP.158 Market Summary161 CHAPTER ELEVEN: RENAL CANCER VACCINES163 Overview163 Description of Vaccines on the Market.166 Oncophage .166 Description of Vaccines in Development.166 vii New Developments in the Cancer Vaccine Ma
20、rket Copyright 2006 Kalorama Information Reproduction without prior written permission, in any media now in existence or hereafter developed, In whole or in any part, is strictly prohibited. Oncophage166 Reniale167 TroVAX.167 IMA901.167 AGS-003167 MDX-1106 168 MKC1106-PP168 Market Summary170 Potenti
21、al Competitors and Analysis, 2012.173 CHAPTER TWELVE: BRAIN CANCER VACCINES199 Overview.199 Glioblastoma.199 Neuroblastoma199 Description of Vaccines in Development.203 DCVax-Brain203 CDX-110.203 GliAtak203 Oncophage203 Market Summary206 CHAPTER THIRTEEN: BLADDER CANCER VACCINES207 Overview.207 Desc
22、ription of Vaccines on the Market211 BCG Therapy (OncoTICE- Organon Teknika) (Immucyst-Sanofi Pasteur)(Pacis- Shire Pharmaceuticals).211 Description of Vaccines in Development.211 Bexidem.211 CG0070.212 MDX-1307-01.212 Market Summary214 CHAPTER FOURTEEN: OVARIAN CANCER VACCINES.199 Overview.199 Desc
23、ription of Vaccines in Development.203 OVax Autologous Cell Vaccine.203 Lapuleucel-T.203 Tumor Associated Antigen Therapeutic Vaccine CEA DNA Cancer Vaccine.204 MKC1106-PP204 Market Summary206 Table of Contents viii Copyright 2006 Kalorama Information Reproduction without prior written permission, i
24、n any media now in existence or hereafter developed, In whole or in any part, is strictly prohibited. CHAPTER FIFTEEN: LEUKEMIA VACCINES.199 Overview199 Description of Vaccines in Development.204 GVAX204 PR1 Peptide Vaccine204 AGS-005.204 Market Summary206 CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTIN
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- Emerging Cancer Vaccines:Market Forecasts New Developments and Pipeline Analysis 3rd Edition Vaccines
链接地址:https://www.31doc.com/p-3755935.html